![]() |
|
|
Vol. 30, Issue 11, 1246-1249, November 2002
College of Pharmacy (Y.C., H-H.S.C.) and Arizona Cancer Center
(Y.C., N.D.A., H-H.S.C.), the University of Arizona, Tucson, Arizona
Green tea and green tea catechins have been shown to possess potent
cancer-preventive activities in rodent cancer models. At present,
epidemiological evidence of the protective effect of green tea
consumption against the development of human cancers is not conclusive.
Oral bioavailability of green tea catechins has been shown to be low in
animals and possibly in humans. This study is designed to determine the
contribution of first-pass hepatic elimination to the low oral
bioavailability of green tea catechins. Green tea catechin mixture was
dosed to rats by intravenous or intraportal infusion. Blood samples
were collected after dosing and analyzed using high-performance liquid
chromatography with the coulometric electrode array detection system.
The systemic clearance of epigallocatechin gallate (EGCG),
epigallocatechin (EGC), and epicatechin (EC) was 8.9, 6.3, and 9.4 ml/min, respectively. The steady state volume of distribution
(Vss) of EGCG, EGC, and EC was 432, 220, and
187 ml, respectively. We found that high percentage of green tea
catechins escaped first-pass hepatic elimination, with 87.0, 108.3, and
94.9% of EGCG, EGC, and EC, respectively, available in the systemic
blood following intraportal infusion. Our results suggest that factors
within the gastrointestinal tract such as limited membrane
permeability, transporter mediated intestinal secretion, or gut wall
metabolism may contribute more significantly to the low oral
bioavailability of green tea catechins.
This article has been cited by other articles:
![]() |
C. E. Isaacs, G. Y. Wen, W. Xu, J. H. Jia, L. Rohan, C. Corbo, V. Di Maggio, E. C. Jenkins Jr., and S. Hillier Epigallocatechin Gallate Inactivates Clinical Isolates of Herpes Simplex Virus Antimicrob. Agents Chemother., March 1, 2008; 52(3): 962 - 970. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Lambert, S. Sang, J. Hong, S.-J. Kwon, M.-J. Lee, C.-T. Ho, and C. S. Yang Peracetylation as a Means of Enhancing in Vitro Bioactivity and Bioavailability of Epigallocatechin-3-Gallate Drug Metab. Dispos., December 1, 2006; 34(12): 2111 - 2116. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Lambert, M.-J. Lee, H. Lu, X. Meng, J. J. J. Hong, D. N. Seril, M. G. Sturgill, and C. S. Yang Epigallocatechin-3-Gallate Is Absorbed but Extensively Glucuronidated Following Oral Administration to Mice,2 J. Nutr., December 1, 2003; 133(12): 4172 - 4177. [Abstract] [Full Text] [PDF] |
||||